CORE ONE LABS INC - CLABF STOCK NEWS

Welcome to our dedicated page for CORE ONE LABS news (Ticker: CLABF), a resource for investors and traders seeking the latest updates and insights on CORE ONE LABS stock.

Core One Labs Inc. (CLABF) is a pioneering life sciences biotechnology research and development company focusing on psychedelic medicines. The company, through its subsidiaries, is dedicated to bringing psychedelic compounds to market, advancing psychedelic-assisted treatments, and integrating novel delivery systems technology. With a multifaceted business approach, Core One holds a key interest in developing proprietary psilocybin production systems and formulations targeting neurological and mental health disorders. Their recent achievements include conducting animal model studies to evaluate bio-compounds' effectiveness in treating diseases like Alzheimer's, Parkinson's, Stroke, and Depression, showing promising results that could revolutionize the treatment landscape.

12/08/2023 06:55 PM

News

Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market

Rhea-AI Summary

Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN:A3CSSU) is pleased to announce the signing of an Initial Agreement with Cube Psytech Corp. marking a significant step towards exploring the potential sale of biosynthetically produced psilocybin or the licensing of its proprietary method for biosynthetic psilocybin production technology. This Agreement could set the stage for Core One products to enter the international market. Cube Psytech is a Canadian bio-pharmaceutical and biotechnology company focused on psilocybin and psilocin research and development programs designed to create innovative drugs and protocols for clinical trials and patient prescribed uses globally. Core One, leveraging its wholly-owned subsidiaries, has successfully developed a proprietary method for the manufacturing of biosynthetic psilocybin and synthetic psilocin. The successful conclusion of any sale or licensing transaction with Cube Psytech remains contingent on several conditions, including the satisfactory completion of due diligence by each party, the negotiation and execution of definitive documentation, and compliance with applicable laws in Core One's and Cube Psytech's operating jurisdictions.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

30.2%

Tags

12/01/2023 07:00 PM

News

Core One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment Methods

Rhea-AI Summary

Core One Labs Inc. (COOL) has announced promising results from its first round of Stage 2 animal model studies in collaboration with Universitat de Barcelona for its subsidiary, Akome Biotechnologies Inc. The studies demonstrate potential for innovative treatment alternatives for Alzheimer's and Parkinson's, marking a significant step forward in the field of neuroscience and psychedelics.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

35.25%

Tags

08/04/2023 07:25 PM

News

Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease

Rhea-AI Summary

Core One Labs Inc. (CSE:COOL) (OTCQB:CLABF) (Frankfurt:LD6, WKN:A3CSSU) Announces Positive Results from Round 2 of Stage 1 Animal Model Studies

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

13.3%

Tags

08/01/2023 07:55 PM

News

Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass

Rhea-AI Summary

Core One's wholly-owned subsidiary, Awakened Biosciences, has filed a patent application for isolating and purifying psilocybin from mushroom biomass. This breakthrough allows Core One to enter the mushroom cultivation market and offer cutting-edge solutions for extracting active ingredients. It positions the company to capitalize on the emerging medical and recreational psychedelics market, similar to the cannabis industry. The patent complements Core One's existing production methods and provides a safe and consistent supply of psilocybin.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.57%

Tags

07/28/2023 07:25 PM

News

Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

4.57%

Tags

07/11/2023 07:25 PM

News

Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-7.5%

Tags

07/07/2023 05:55 PM

News

Core One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production Method

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

15.72%

Tags

05/05/2023 07:25 PM

News

Core One in Talks with Multiple Companies to Supply Psilocybin

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.59%

Tags

05/01/2023 08:25 PM

News

Core One Labs' GMP Drug Takes Further Steps Toward Commercialization: Initiating Development of Psychedelic Prodrugs with Long-established Compounding Pharmacy

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.81%

Tags

04/21/2023 07:55 PM

News

Core One's Awakened Completes Successful Synthetic Production of Psilocin in its GMP Certified Manufacturing Facility

Rhea-AI Summary

Core One Labs Inc. (OTCQB:CLABF) has marked a significant milestone with the successful synthetic production of psilocin at its GMP facility, achieved by its subsidiary Awakened Biosciences Inc.. This development showcases operational synergies from a recent acquisition, enhancing the company's strategic goal of becoming a large-scale supplier of psychedelic compounds. CEO Joel Shacker emphasized that this achievement is foundational for future production and research of psilocybin and other psychedelic compounds. The production was led by Dr. Tony Durst, a specialist in medicinal chemistry, who aims to advance innovations in psychedelics research. Awakened currently holds three provisional patents for psilocybin production methods, further solidifying Core One's position in the emerging psychedelics market.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

11.84%

Tags

FAQ

What is the current stock price of CORE ONE LABS (CLABF)?

The current stock price of CORE ONE LABS (CLABF) is $0.1284 as of June 7, 2024.

What is the market cap of CORE ONE LABS (CLABF)?

The market cap of CORE ONE LABS (CLABF) is approximately 7.4M.

What is Core One Labs Inc. known for?

Core One Labs Inc. is known for its focus on bringing psychedelic medicines to market, developing proprietary psilocybin production systems, and advancing psychedelic-assisted treatments.

What are some recent achievements of Core One Labs Inc.?

Core One Labs Inc. recently conducted animal model studies to evaluate bio-compounds' effectiveness in treating Alzheimer's, Parkinson's, Stroke, and Depression, showing promising results.

What is the business approach of Core One Labs Inc.?

Core One Labs Inc. has a multifaceted business approach, incorporating several complementary lines of businesses to establish itself as an industry leader in the rapidly growing psychedelics market space.

How does Core One Labs Inc. differentiate itself in the market?

Core One Labs Inc. stands out by focusing on the development of innovative psychedelic compounds, psychedelic-assisted treatments, and novel delivery systems technology to address neurological and mental health disorders.

What are the potential benefits of Core One Labs Inc.'s animal model studies?

The animal model studies conducted by Core One Labs Inc. have shown promising results, indicating the potential for transformative advancements in developing psychedelic drug formulations to target Parkinson's, Alzheimer's, Stroke, and Depression effectively.